We are live on ! Find out more
LRMR icon

Larimar Therapeutics
LRMR

89 hedge funds and large institutions have $304M invested in Larimar Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 21

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

17% more capital invested

Capital invested by funds: $260M → $304M (+$44M)

2% more funds holding

Funds holding: 87 → 89 (+2)

1.77% less ownership

Funds ownership: 7.65% → 5.88% (-1.8%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

94% less call options, than puts

Call options by funds: $7K | Put options by funds: $126K

Holders
89
Holders Change
+2
Holders Change %
+2.3%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
12
Increased
45
Reduced
21
Closed
10
Calls
$7K
Puts
$126K
Net Calls
-$119K
Net Calls Change
-$513K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.6M
2
BlackRock
BlackRock
New York
+$6.92M
3
GTC
Ghost Tree Capital
New York
+$6.55M
4
Citadel Advisors
Citadel Advisors
Florida
+$5.52M
5
FCM
Farallon Capital Management
California
+$3.63M

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$16.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.8M
3
AG
Artal Group
Luxembourg
-$4.05M
4
AC
Armistice Capital
New York
-$3.4M
5
ACP
Acuta Capital Partners
California
-$2.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
GIM
26
Granahan Investment Management
Massachusetts
$2.53M +$1.49M +12,258 +211%
TG
27
TRV GP
Massachusetts
$2.46M – – –
Deutsche Bank
28
Deutsche Bank
Germany
$1.94M +$695K +5,726 +71%
Goldman Sachs
29
Goldman Sachs
New York
$1.89M +$1.01M +8,335 +163%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.83M +$289K +2,378 +22%
BCM
31
Bridgeway Capital Management
Texas
$1.19M – – –
Two Sigma Investments
32
Two Sigma Investments
New York
$1.16M +$596K +4,914 +146%
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
$1.13M -$26.3K -217 -3%
SIM
34
Spark Investment Management
New York
$1.1M -$44.5K -367 -4%
DCM
35
DAFNA Capital Management
California
$1M -$784K -6,461 -47%
KC
36
Kepos Capital
New York
$978K – – –
AG
37
Algert Global
California
$865K +$555K +4,574 +288%
Charles Schwab
38
Charles Schwab
California
$793K +$255K +2,098 +59%
EI
39
EAM Investors
California
$761K +$430K +3,541 +188%
TD Asset Management
40
TD Asset Management
Ontario, Canada
$662K +$573K +4,717 New
TA
41
Teachers Advisors
New York
$637K +$252K +2,075 +84%
TCIM
42
TIAA CREF Investment Management
New York
$619K +$181K +1,492 +51%
Morgan Stanley
43
Morgan Stanley
New York
$589K +$6.68K +55 +1%
Squarepoint
44
Squarepoint
New York
$551K +$348K +2,867 +271%
AP
45
AlpInvest Partners
Netherlands
$547K -$947K -7,800 -67%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$542K +$116K +954 +33%
AQR Capital Management
47
AQR Capital Management
Connecticut
$481K +$255K +2,099 +158%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$472K +$153K +1,259 +60%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$277K +$240K +1,975 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$276K +$27.3K +225 +13%
1
2
3 4

LRMR Hedge Fund Activity: Q3 2018 in Review

89 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2018, worth a combined $304M — up 17% from $260M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LRMR positions and 10 closed out — a net gain of 2 holders — while 45 added to existing stakes and 21 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $12.6M. The largest seller was 683 Capital Management, exiting entirely with an estimated $16.4M sold.

  • 89 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2018, up from 87 in Q2 2018.
  • Funds reported $304M of Larimar Therapeutics stock for Q3 2018, up 17% quarter-over-quarter.
  • 12 funds opened new Larimar Therapeutics positions in Q3 2018 and 10 closed out, a net change of +2 holders.
  • The largest Larimar Therapeutics buyer in Q3 2018 was T. Rowe Price Associates, an estimated $12.6M added.
  • The largest Larimar Therapeutics seller in Q3 2018 was 683 Capital Management, an estimated $16.4M sold.

Based on aggregated 13F filings for Q3 2018.